| 13.5 -0.24 (-1.75%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.74 |
1-year : | 19.23 |
| Resists | First : | 15.19 |
Second : | 16.46 |
| Pivot price | 14.2 |
|||
| Supports | First : | 13.11 |
Second : | 10.91 |
| MAs | MA(5) : | 13.61 |
MA(20) : | 14.61 |
| MA(100) : | 12.63  |
MA(250) : | 10.45 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 8.2 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 16.46 | Low : | 6.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VTRS ] has closed above bottom band by 21.4%. Bollinger Bands are 42.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.89 - 13.98 | 13.98 - 14.06 |
| Low: | 12.95 - 13.03 | 13.03 - 13.11 |
| Close: | 13.37 - 13.51 | 13.51 - 13.64 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Thu, 19 Mar 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - ChartMill
Thu, 19 Mar 2026
$11B cash by 2030 gives Viatris room for deals and shareholder returns - Stock Titan
Thu, 19 Mar 2026
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for Investors - Contact Levi & Korsinsky - The National Law Review
Sun, 15 Mar 2026
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Yahoo Finance
Fri, 13 Mar 2026
UBS and BofA Lift Price Targets on Viatris (VTRS) - Yahoo Finance
Tue, 03 Mar 2026
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,150 (M) |
| Shares Float | 1,140 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 87.4 (%) |
| Shares Short | 26,450 (K) |
| Shares Short P.Month | 25,270 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.77 |
| Profit Margin | -24.6 % |
| Operating Margin | 7.7 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | -21.1 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 4.92 |
| Sales Per Share | 12.43 |
| EBITDA (p.s.) | 3.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,320 (M) |
| Levered Free Cash Flow | 2,430 (M) |
| PE Ratio | -4.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 1.08 |
| Price to Cash Flow | 6.69 |
| Dividend | 0.11 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|